European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm
Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis…
17/09/2019 - 4 minutes
GeNeuro
Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis
An antibody that blocks the action of a hidden viral protein encoded by our genome…
12/03/2019 - 3 minutes
Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II
GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in…
26/03/2018 - 2 minutes
This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease
The FDA has awarded Orphan Drug Designation to GeNeuro's antibody for the treatment of a…
26/02/2018 - 2 minutes
Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis
A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in…
01/11/2017 - 2 minutes
In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight
Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United…
30/05/2017 - 7 minutes
How Biotech is Mastering Multiple Sclerosis: A Review
With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis.…
25/04/2017 - 7 minutes
Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment
GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company's CFO, who…
30/09/2016 - 1 minute
First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!
We last wrote about GeNeuro in January, when they announced the launch of an IPO…
16/04/2016 - 2 minutes
Will there be a New Merck-Serono?
GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought…
15/12/2014 - 2 minutes
